A Phase 1/2 Open-label Study Investigating the Safety Tolerability and Efficacy of ASP7517 in subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) | NYU Langone Health

Go Back to All Clinical Trials

A Phase 1/2 Open-label Study Investigating the Safety Tolerability and Efficacy of ASP7517 in subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Relapsed/refractory Acute Myeloid Leukemia (aml) And Relapsed/refractory Higher Risk Myelodysplastic Syndrome (mds)
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Subject diagnosed with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS). 2) Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of = 2. 3) Subjects with AML must have peripheral blood absolute blast count of < 20,000/µL at C1D1.

You may not be eligible for this study if the following are true:

1) Subject was diagnosed with acute promyelocytic leukemia. 2) Subject has breakpoint cluster region-Abelson-positive leukemia (BCR-ABL). 3) Subject has persistent non-hematological toxicities of = grade 2 (National Cancer Institute’s Common Terminology Criteria for Adverse Events [NCI-CTCAE]. 4) Subject has clinically active nervous system leukemia, per the investigator’s judgment.